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Abstract
Purpose: The main purpose of this study was to understand how the positron emission
tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein varies in vivo during the
development of temporal lobe epilepsy (TLE) in the kainic acid rat model.
Procedures: Twenty Sprague Dawley male rats were administered with multiple systemic doses
of saline (control group, n = 5) or kainic acid (5 mg/kg/injection, epileptic group, n = 15). Both
groups were scanned at the four phases of TLE (early, latent, transition, and chronic phase) with
the [18F]UCB-H PET radiotracer and T2-structural magnetic resonance imaging. At the end of
the scans (3 months post-status epilepticus), rats were monitored for 7 days with electroen-
cephalography for the detection of spontaneous electrographic seizures. Finally, the immuno-
fluorescence staining for SV2A expression was performed.
Results: Control rats presented a significant increase in [18F]UCB-H binding at the last two scans,
compared with the first ones (p G 0.001). This increase existed but was lower in epileptic animals,
producing significant group differences in all the phases of the disease (p G 0.028). Furthermore, the
quantification of the SV2A expression in vivo with the [18F]UCB-H radiotracer or ex vivo with
immunofluorescence led to equivalent results, with a positive correlation between both.
Conclusions: Even if further studies in humans are required, the ability to detect a progressive
decrease in SV2A expression during the development of temporal lobe epilepsy supports the
use of [18F]UCB-H as a useful tool to differentiate, in vivo, between healthy and epileptic animals
along with the development of the epileptic disease.
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Introduction
Worldwide, around 50 million people suffer from epilepsy,
a neurological chronic disorder characterized by recurrent
and unprovoked seizures [1]. Nevertheless, approximately
30 % of the patients are unresponsive to the available
treatments. Thus, studying the underlying pathophysiology
of this disease is essential for the discovery of more
efficient treatments [2, 3]. In this regard, the development
and preclinical evaluation of new positron emission
tomography (PET) radiotracers has provided new longitu-
dinal insights on the neurobiological processes affected by
epilepsy [4, 5]. Among them, two have been extensively
investigated: (1) alterations in the glucose metabolism of
the brain, quantified through [18F]-fluoro-2-deoxy-D-glu-
cose ([18F]FDG) radiotracer [6, 7], and (2) neuroinflam-
matory processes, detected with different translocator
protein (TSPO) markers [8–10]. Over the last few years,
a third potential biomarker has drawn attention to the
scientific community: (3) the determination of synaptic
density through the evaluation of the synaptic vesicle 2A
(SV2A) protein [11–14].
SV2A is a transmembrane glycoprotein involved in the
synaptic transmission, whose expression in the brain is
ubiquitous [15–17]. Genetically, the homozygous mutation
of this protein has been associated with intractable epilepsy,
growth retardation, and premature death, both in animals
[18, 19] and in humans [20]. Furthermore, different studies
have identified the SV2A protein as the target of one of the
most effective antiepileptic drugs: levetiracetam [17, 21].
Therefore, an important link between the altered SV2A
expression and/or function and the epileptic process is
expected. This potential link has encouraged the continuous
development of different radiotracers to perform the in vivo
evaluation of this protein. Among them, two have been
widely characterized: [18F]UCB-H [22–26] and [11C]UCB-J
[14, 27, 28].
In this paper, we performed the first in vivo longitudinal
study of variations in SV2A expression in the kainic acid
(KA) rat model of temporal lobe epilepsy (TLE). This model
reproduces the different phases of the epileptogenic process
in patients [29, 30]: early phase (initial precipitating insult or
status epilepticus (SE)), latent phase (seizure-free period),
transition phase (onset of first spontaneous seizures), and
chronic phase (recurrent and spontaneous seizures). Varia-
tions in SV2A levels, measured in vivo with [18F]UCB-H
radiotracer, were quantified in these four phases. Addition-
ally, at the end of the PET scans, we tested for a possible
correlation between variations in SV2A expression and the
occurrence of electrographic seizures. Finally, we performed
SV2A immunofluorescence on brain slices of the same
animals, to confirm the [18F]UCB-H in vivo results.
Materials and Methods
Animals
Twenty Sprague Dawley CD male rats, from 4 to 5 weeks
old, were obtained from Janvier Laboratories (France). The
minimum sample size for the experiment (n = 4) was
estimated with the G*Power software (G*Power, v 3.0),
setting the power level at 0.8 and the alpha level at 0.05.
These parameters were established to detect large effect size
differences between groups (ƞ2 9 0.5), based on a pilot study
performed in our laboratory.
During the PET and MRI procedures, the animals were
housed in pairs under a 12 h:12 h light-dark cycle, while
maintaining the room temperature at 22 °C, and the humidity
at approximately 50 %. During the EEG recording experi-
ments, however, the animals were housed individually.
Standard pellet food and water were provided ad libitum.
Induction of the Temporal Lobe Epilepsy Model
According to the procedure of Hellier [31, 32], fifteen rats
(epileptic group) received multiple systemic injections (IP)
from 2.5 to 5 mg/kg of kainic acid (KA monohydrate ≥
99 %, Sigma-Aldrich, USA) every 30 min, until they
displayed several stage 5 generalized tonic-clonic seizures
per hour (convulsive SE) [33]. Four rats were excluded from
the experiment since they did not develop SE. The average
KA dose per rat amounted to 18.5 ± 4 mg/kg. Simulta-
neously, a saline solution was administrated to five
additional rats, which constitute the control group. SE was
not interrupted with medication.
Experimental Design
Figure 1 presents the experimental design used in this study
with all the different techniques, the number of animals
employed, and the average age of the animals at the various
measurement points.
Briefly, after the administration of KA (n = 11) or saline
(n = 5), the animals were scanned at four time points,
corresponding with the different phases of the TLE: (1)
early phase (24 h), (2) latent phase (3 to 6 days), (3)
transition phase (30 to 45 days), and (4) chronic phase (90 to
105 days). For all 4 phases, we performed [18F]UCB-H PET
scans to quantify variations in SV2A, as well as structural
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T2-weighted MRI scans, to detect changes in brain structure.
Four days after the last scan, a recording electrode was
implanted into the hippocampus of the epileptic rats, and
after 2 days of recovery, hippocampal EEG was continu-
ously recorded for 1 week. On the last day of recording, rats
of both groups were transcardially perfused and their brains
were extracted. Then, immunofluorescence (IF) was per-
formed to quantify the SV2A protein levels in the brain.
PET and MRI Imaging
Before each scan session, the health of each rat was
assessed. The animals that did not completely recover from
the previous scans, or with a slight decrease in activity,
unkempt hair coat or significantly thinner, were not scanned.
Furthermore, the respiration rate and the rectal temperature
were continuously measured during the PET and MRI scans,
using a monitoring system. The temperature was maintained
at 37 ± 0.5 °C using an air warming system (Minerve,
France).
[18F]UCB-H Scans The enantiomerically pure [18F]UCB-
H was produced through one-step radiolabeling of a
pyridyliodonium precursor in accordance with a reported
method, obtaining a molar activity around 10 Ci/μmol [34].
The acquisition protocol was performed in different steps.
First, the rats were anesthetized with a mixture of air with
30 % oxygen and isoflurane (4 % induction and 1.5–2 % for
maintenance). Then, [18F]UCB-H (37 ± 4 MBq, 0.55 mL)
was administered via the caudal vein (i.v.), and simulta-
neously, the PET emission data were recorded during 60 min
in list mode on a Siemens FOCUS 120 microPET (Siemens,
Knoxville, TN). Subsequently, a 10-min PET transmission
scan was run in single event acquisition mode, using a 57Co
source. The necessary information regarding data recon-
struction and image specifications are detailed in previous
works [35, 36].
MRI Scans Following the PET acquisitions, the rats were
transferred into the MRI (9.4T/310 ASR horizontal bore
Agilent system), and anatomical T2-weighted brain images
were obtained with a fast spin-echo multi-slice sequence,
using the parameters detailed in [35, 36]. Owing to the small
size of the rats during the two first phases, a surface rat coil
was used in order to increase the signal-to-noise ratio (Rat
Head Phased Array, 400 MHz, Rapid Biomedical GmbH,
Würzburg, Germany).
Imaging Data Processing The image data were processed
using two software: SPM8 (Welcome Department of
Cognitive Neurology, London, UK) and PMOD 3.6 (PMOD
Technologies, Zurich, Switzerland).
[18F]UCB-H Quantification A recently published method-
ology was used to quantify the uptake of the [18F]UCB-H
radiotracer in the rat brain [35]. This methodology consists
of using the standardized uptake value parameter (SUV),
calculated on the average image corresponding to the 20 to
40-min time window after the radiotracer injection since this
parameter is highly correlated with Vt in the case of the
[18F]UCB-H radiotracer [35].
Fig. 1 Experimental design. After the administration of multiple systemic doses of saline (control group) or kainic acid (KA,
epileptic group), the animals were scanned at 4 time points, corresponding to the four phases of the TLE, with the [18F]UCB-H
PET radiotracer, and with MRI. Subsequently, the EEG pattern of epileptic animals was recorded during 24 h per day, for
7 days. At the end of the last EEG measurement, all the rats were perfused, and the immunofluorescence labeling was
performed to determine SV2A-expression levels. SE = status epilepticus; EEG = electroencephalography; IF =
immunofluorescence.
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For each animal, the structural MRI image obtained at
every phase was manually co-registered with the
corresponding PET image, and subsequently, rigid body
transformations were applied. Then, the obtained MRI image
was spatially normalized into the PMOD structural MRI
template. Finally, the inversed normalization parameters
were calculated and applied to the modSchiffer atlas (Suppl.
Fig. 1) in order to bring it into the individual PET space.
From this atlas, created to adapt the PMOD’s rat atlas (W.
Schiffer) to the morphology of the epileptic group, six ROIs
were chosen: amygdala, striatum, hippocampus, thalamus,
hypothalamus, and cortex. The radioactivity concentrations,
extracted from the different ROIs, were expressed in SUV
by means of its normalization by the injected dose and the
animal body weight.
EEG Surgery and Recordings
Surgery for EEG recordings was performed as described
previously [37]: the epileptic rats were anesthetized with a
mixture of air with 30 % oxygen and isoflurane (4 %
induction and 2–2.5 % for maintenance). Additionally,
0.2 mg/kg of xylocaine was subcutaneously injected as local
anesthesia. Small burr holes were drilled into the skull of the
animals: eight for the positioning of anchor screws, one for
an epidural screw electrode (above right frontal cortex), one
for the reference/ground electrode (above left frontal cortex),
and one for a custom-made polyimide-coated bipolar
electrode (see Suppl. Fig. 2a). This bipolar recording
electrode was placed in CA1 and in the hilus of the dentate
gyrus using electrophysiological feedback (coordinates
relative to Bregma: – 0.58 AP, + 0.40 ML, + 0.26/+
0.35 DV, respectively). Immediately after surgery, the rats
were injected subcutaneously with Metacam (2 mg/kg), and
an ointment of Lidocaine and Neobacitracine was applied to
the wound. Once finished the procedure, the rats were
individually housed for 2 to 4 days before starting the EEG
recording.
EEG data were analyzed with Matlab R2017a (The
MathWorks, Inc., Natick, USA) by two experts, blinded to
the PET results. The electrographic seizures were defined as
described in [6, 37]: episodes of rhythmic spiking activity
with a high amplitude (9 3 × baseline) and frequency (9
5 Hz), with a duration of, at least, 10 s (see Suppl. Fig. 2b).
Three parameters were evaluated per animal: the number of
electrographic seizures per week (seizures/week), their mean
duration (seconds/seizure), and the total time in seizures
(total seconds).
Perfusion and Brain Pre-Treatments
At the end of 1 week of EEG recording, all the surviving rats
of both groups were deeply anesthetized with pentobarbital
(180 mg/kg, i.p.) and transcardially perfused with
phosphate-buffered saline (PBS) followed by 4 %
paraformaldehyde (PFA). The brains were extracted, post-
fixed overnight at 4 °C in 4 % PFA solution, and
cryoprotected for 3 to 5 days with increasing concentrations
of sucrose (10 %, 20 %, and 30 %). Finally, the brains were
frozen in isopentane at − 35 °C and serially sliced in 30 μm
coronal sections with a cryostat (Leica, Germany). Slices
from the striatum (Bregma, 1.92 to 1.20 mm) and the
hippocampus (Bregma, − 2.64 to − 3.60 mm) were mounted
onto coated glass slides (Premium Gelatin Subbed Slides,
Southern Biotech MS, USA) and stored at − 80 °C.
SV2A Immunofluorescence
Experiments were performed in duplicate, using a negative
control to guarantee the primary antibody specificity for the
SV2A protein. Additionally, glial fibrillary acidic protein
(GFAP) immunofluorescence staining was used as a positive
control for tissue quality.
The immunofluorescence staining procedure was per-
formed as follows: firstly, slices were tempered, rinsed in
PBS, and heated for 15 min in citrate buffer (pH 6.0) at 95 ±
3 °C for antigen retrieval. Thereafter, they were washed
three times with a mixture of PBS and 0.05 % Tween20
(PBST, pH 7.5) and permeabilized for 10 min with 0.3 %
Triton × 100. Slides were then incubated for 1 h with a
blocking solution containing PBST and 10 % donkey serum
(Sigma-Aldrich, St. Louis, USA). Immediately after, primary
antibodies (polyclonal rabbit anti-SV2A, dilution 1:200;
Abcam, Cambridge, MA; or polyclonal rabbit anti-GFAP,
dilution 1:500, DAKO, Denmark) were applied overnight at
4 °C, in blocking solution. Following three washes with
PBST, slides were incubated for 45 min with the secondary
antibody (donkey anti-Rabbit Alexa Fluor 488-conjugated,
dilution 1:500/1:1000 respectively; Thermo Fisher, OR,
USA). Sections were washed with PBS, and nuclei were
counterstained for 10 min with 300 nM DAPI in PBS
(Thermo Fisher, OR, USA). Finally, slides were washed in
PBS and distilled water and coverslipped with antifade
medium (Fluoromount-G, Southern Biotechnology, Bir-
mingham, AL, USA).
Confocal fluorescence images of the cortex (motor area),
the caudate/putamen, and the different hippocampal struc-
tures (pyramidal cell layer of CA1 and CA3, and the hilus of
the DG) were obtained using a scanning laser microscope
(Leica TCS SP5 with AOBS, Leica Microsystems IR
GmbH, Germany) with a × 20 objective. Images obtained
with a × 10 objective were used only for presentation
purposes. SV2A-immunoreactivity was quantified by mea-
suring the optical density (OD) after background subtraction,
using the ImageJ software (ver. 1.8.0, NIH).
Statistical Analyses
Statistical analyses were carried out with SPSS (IBM®
SPSS® Statistics 25; USA), setting the critical threshold of
Serrano M.E. et al.: Longitudinal in vivo SV2A evaluation in temporal lobe epilepsy
statistical significance at p G 0.05 for all the tests. Further-
more, the false discovery rate (FDR) was applied in all the
statistical analyses to correct for multiple comparisons.
Excel (2010) was used to graphically represent the results,
expressed as the mean ± SEM.
[18F]UCB-H Data The linear mixed-effects (MIXED)
analysis and a restricted maximum likelihood (REML)
estimation were used to longitudinally assess 1) changes
in [18F]UCB-H uptake in control animals (n = 4–5) due
to the brain development and 2) possible differences in
[18F]UCB-H uptake between control and epileptic (n = 9–
11) rats [38]. The assumptions of normality and
homogeneity of residuals were previously evaluated with
Levene’s and Kolmogorov-Smirnov tests. To challenge
our hypothesis, significant effects and interactions be-
tween the variables group and phases were assessed via
LSD test, followed by the FDR correction for multiple
comparisons.
[18F]UCB-H and EEG Data Since the three EEG
parameters (seizures/week, seconds/seizure, and total
seconds) were not normally distributed (Shapiro-Wilk
test, p 9 0.05), the Spearman’s rho method was employed
to evaluate the relationship between these parameters and
the [18F]UCB-H data for the chronic phase, in the
epileptic group (n = 8).
SV2A Immunofluorescence The independent samples t test
(Student’s t test) was used to statistically compare SV2A-
immunoreactivity between the two groups (control, n = 4;
epileptic, n = 8). Additionally, the correlation between the
OD and the [18F]UCB-H uptake (SUV) during the chronic
phase was evaluated by means of Pearson’s r correlation
coefficient.
Results
PET and MRI Imaging
[18F]UCB-H Results The variations in [18F]UCB-H uptake
(SUV) over time were analyzed in control (n = 4 to 5) and
epileptic (n = 9 to 11) groups (see Fig. 2).
Y Longitudinal variations of [18F]UCB-H uptake in control
animals
The statistical analysis highlighted a significant increase
in [18F]UCB-H uptake through the aging process, in all
ROIs: hippocampus (F3,4 = 13.00; p G 0.05), amygdala
(F3,5 = 14.98; p G 0.01), cortex (F3,4 = 10.80; p G 0.05), stria-
tum (F3,4 = 11.62; p G 0.05), thalamus (F3,5 = 14.03; p
G 0.01), and hypothalamus (F3,8 = 17.96; p G 0.01). Further
pairwise comparisons showed that the differences between
any of the first two (38 and 42 days old, puberty) and any of
the last two (80 days old or young adults and 145 days old
or mature adults) scans were statistically significant, with
p G 0.05. In addition, in the amygdala and the hypothalamus,
it was also possible to detect statistically significant differ-
ences between animals aged 80 (young adults) and 145 days
(mature adults).
Y Comparison of [18F]UCB-H uptake between control and
epileptic animals
The comparison between control and epileptic animals
highlighted the existence of significant differences between
both groups, showing the latter a decreased uptake in all the
ROIs (Fig. 3): hippocampus (F1,47 = 47.46; p G 0.001),
amygdala (F1,37 = 80.01; p G 0.001), cortex (F1,46 = 29.47;
p G 0.001), striatum (F1,43 = 43.37; p G 0.001), thalamus
(F1,47 = 40.72; p G 0.001), and hypothalamus (F1,46 = 30.71;
p G 0.001). The mean difference between the control and the
epileptic group increases from 12 ± 6 (early phase) to 22 ±
2 % (chronic phase), with the amygdala presenting the
Fig. 2 Representative images of longitudinal follow-up of variations in [18F]UCB-H uptake. The transaxial brain slices represent
the [18F]UCB-H uptake of one representative animal of each group. Scans were performed at four time points, corresponding to
the different phases of the TLE model.
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largest differences between groups. Further pairwise com-
parisons highlighted statistically significant differences
between groups already during the early phase (24 h post-
SE), in four regions: the amygdala (p = 0.002), the striatum
(p = 0.002), the thalamus (p = 0.021), and the hypothalamus
(p = 0.021). Interestingly, these group differences disap-
peared in the striatum, the thalamus, and the hypothalamus
during the latent phase (3 to 6 days post-SE), while they
appeared in the hippocampus (p = 0.023). At late phases
(transition and chronic phase), the group differences in
[18F]UCB-H uptake were global, with p G 0.001 in all the
regions.
Finally, the interaction between the variables group and
phases was not statistically significant in any of the regions
(p G 0.05), which indicates that the epileptic animals pre-
sented an increase in [18F]UCB-H uptake through time
equivalent to the one observed in control animals. However,
this increase was lower in the epileptic group (22 ± 3 %)
compared with the control one (around 36 ± 2 %).
MRI and Structural Brain Deformations Structural brain
alterations were present during the different phases of the
epileptogenesis (Fig. 4): during the early phase, a T2*
Fig. 3 Quantification of variations in [18F]UCB-H uptake. The central figure represents the coronal view of a representative
epileptic rat during the chronic phase (left hemisphere) and the Schiffer PMOD atlas (right hemisphere). Bar plots represent the
[18F]UCB-H uptake (mean ± SEM) of control (n = 4–5) and epileptic groups (n = 9–11). Significant differences (p G 0.05) between
one phase and the precedents are represented by letters, with: a= early phase (24 h), b = latent phase (3-6d), c = transition
phase (30–45 days). Significant differences between groups are represented by stars.
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hyperintensity was detected in temporal regions like the
amygdala and the entorhinal cortex, disappearing during the
latent phase. During the transition and chronic phases, the
progressive atrophy in the hippocampus and the amygdala is
remarkable. Furthermore, we can observe a continuous
increase in the ventricular CSF volume, which is more
prominent in the lateral ventricles.
[18F]UCB-H and EEG A strong inter-subject variability
was seen in seizure parameters: the number of electrographic
seizures per week ranged from 0 to 299, their mean duration
ranged from 42 to 93 s, and the total time in seizures ranged
from 0 to 12,139 s (see Table 1). However, the 2-tailed
Spearman’s rho correlation did not reveal any significant
correlation between these EEG parameters and the
[18F]UCB-H uptake, with: 0.119 G ρ G 0.738, and p 9 0.05.
SV2A Immunofluorescence Two parameters were checked
prior to performing the SV2A immunofluorescence staining:
(1) the preservation of the brain tissue, evaluated by means
of the astrocyte marker GFAP (Suppl. Fig. 3a), and (2) the
specificity of the primary antibody against the SV2A protein
(Suppl. Fig. 3b).
Subsequently, we performed a SV2A immunofluores-
cence labeling (Fig. 5). The independent samples t test
confirmed the existence of significant group differences
(epileptic vs control) in all the regions analyzed (Fig. 6a):
cortex (t (10) = 5.21; p G 0.003), striatum (t (10) = 3.22; p =
0.01), hilus of the dentate gyrus (t (10) = 3.48; p = 0.009),
CA1 (t (10) = 2.59; p = 0.027), CA3 (t (10) = 4.08; p =
0.004), and in the average of all the hippocampal subregions
(t (10) = 4.70; p = 0.003). The difference between groups
ranged from 29.3 % in the hippocampus to 42.5 % in the
cortex.
The relationship between the results obtained with the
immunofluorescence (OD) and with the [18F]UCB-H radio-
tracer (SUV, chronic phase) was studied by means of the
Pearson correlation. These results confirm a significant
positive correlation between both parameters in all the ROIs
(Fig. 6b): cortex (r = 0.512; p = 0.045), striatum (r = 0.519;
p = 0.045), and hippocampus (r = 0.671; p = 0.024).
Discussion
Understanding the pathological processes associated with
epilepsy is key to the development of new biomarkers and
treatments. In this study, we conducted, for the first time, a
longitudinal in vivo evaluation of the variations of SV2A
expression associated with the development of TLE in the
kainic acid rat model. Additionally, to better understand the
underlying neuropathological processes implicated in epi-
leptogenesis, we assessed the relationship between the
expression of this protein ([18F]UCB-H uptake) and the
characteristics of the electrographic seizures. Before analyz-
ing the results of this study, we confirmed the correct
development of the TLE in the model used by means of two
techniques: MRI and EEG. On the one hand, MRI images
Fig. 4 Longitudinal follow-up of alterations in the structure of the brain. Representative T2-structural MRI scanners, performed
in two groups: a–d control rats, n = 4–5 and e–h epileptic rats, n = 9–11. The animals were scanned at four time points,
corresponding to the different phases of the TLE model.
Table 1 . Results of EEG evaluation in the epileptic group. The table
presents the three parameters analyzed with EEG: the number of electro-
graphic seizures per week (seizures/week), their mean duration (seconds/
seizure), and the total time in seizures during the week of recording (total
seconds), in the epileptic group (n = 8)
Seizures/week Seconds/seizure Total seconds
Epileptic 1 0 seizures 0 s 0 s
Epileptic 2 1 seizure 99.6 s 99.6 s
Epileptic 3 2 seizures 42.4 s 84.7 s
Epileptic 4 4 seizures 93.3 s 373.3 s
Epileptic 5 79 seizures 47.9 s 4270.8 s
Epileptic 6 203 seizures 46.8 s 9982.2 s
Epileptic 7 238 seizures 51.4 s 11,441.5 s
Epileptic 8 299 seizures 47.9 s 12,138.7 s
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present structural brain deformations post-SE, similar to
those reported in the existing literature [4, 39]. On the other
hand, EEG showed clear electrographic hippocampal seiz-
ures. Both techniques, therefore, confirmed the correct
development of the TLE model.
The results obtained with the [18F]UCB-H radiotracer
highlight a significant increase in the SV2A rat brain
expression from 38 (rat puberty) to 80–145 days old (rat
adulthood). These results suggest an increase in this protein
during the rat brain development which, to date, has only
been evaluated from embryonic day E12 to postnatal day
P30 [44]. Since SV2A is a presynaptic protein, this result
could be reflecting an increase in the synaptic connections
along the aging process.
Regarding the results about the comparison between
the two groups, we can observe a lower increase in the
SV2A expression in the epileptic group, compared with
the control one. These group differences, some of them
previously reported in vitro in both, animal models [40,
41] and TLE patients [40, 42, 43], can be detected
in vivo in multiple regions as soon as 24 h post-SE, in
all ROIs. Interestingly, in the hippocampus (epileptic
foci) these differences are not present in the early phase,
but they appear in the latent phase (3 to 6 days post-SE),
increasing in the subsequent phases. This finding is
consistent with one previous in vitro study [40].
Additionally, the longitudinal analysis reveals that the
differences in SV2A expression increase progressively
between the two groups, peaking at the chronic phase in
the amygdala and the hippocampus (around 22 %
difference). Furthermore, these group differences evolve
differently depending on the evaluated ROI. For instance,
the epileptic group presents a recovery in the SV2A
levels during the latent phase (3 to 6 days post-SE) in
four of the six regions: the amygdala, the striatum, the
thalamus, and the hypothalamus. Such a recovery may be
due to different compensatory processes taking place in
response to SE, such as neurogenesis or synaptic
reorganization [45, 46], and seems to be accompanied
by the reabsorption of the oedema which appears in
temporal regions during the acute phase, as we can
observe in the MRI images.
In addition to the analyses of group differences in
SV2A expression, we examined the possible relationship
between variations in this protein and the presence of
electrographic seizures. This evaluation did not reveal
any significant correlation between the [18F]UCB-H
uptake and the three EEG parameters measured: seiz-
ures/week, seconds/seizure, and total seconds. This result
suggests that the variations in SV2A levels may impact
Fig. 5 SV2A immunofluorescence. SV2A immunofluorescence staining was performed in control (n = 4) and epileptic rats
(n = 9). We can observe a SV2A immunoreactivity decrease in the epileptic rat images, compared with the control ones. The
scale bar (bottom right in all figures) represents 150 μm.
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the development of the TLE and the emergence of
seizures, but not on the characteristics of the seizures
(number and duration). However, since the number of
animals employed is only suitable to detect large (and
not medium or small) effect size differences, it would be
necessary to increase the number of animals, in a future
study, to perform a more precise evaluation about the
relationship between the EEG measurements and the
SV2A levels.
Finally, we employed the SV2A immunofluorescence to
confirm these in vivo [18F]UCB-H results and validate our
study. The statistically significant differences between
groups (36 ± 7 %), along with the positive correlation
between both SV2A measures, corroborate the suitability
of [18F]UCB-H as an alternative to the in vitro techniques
currently in use.
Conclusions
In this paper, we have used the [18F]UCB-H radiotracer
to detect variations in SV2A expression in the brain of a
TLE rat model. Throughout this study, we have demon-
strated its suitability to detect differences between control
and epileptic animals and to follow-up on the brain
maturation and the progression of the epileptic disease.
[18F]UCB-H seems to be a promising tool to diagnose
and monitor in vivo the epileptic disease in animal
models and a valuable alternative to the in vitro
immunofluorescence technique. Thus, the use of this
radiotracer opens the door to new research which could
help us to finally understand the role of the SV2A
protein in epilepsy.
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data set. ROD = relative optical density; DG = dentate gyrus; CA = cornu ammonis; HC = hippocampus; OD = optical density.
Serrano M.E. et al.: Longitudinal in vivo SV2A evaluation in temporal lobe epilepsy
Conflict of Interest
The authors declare that they have no conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution
4.0 International License, which permits use, sharing, adaptation, distribu-
tion and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the article's
Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by/4.0/.
References
1. Ngugi AK, Bottomley C, Kleinschmidt I et al (2010) Estimation of the
burden of active and life-time epilepsy: a meta-analytic approach.
Epilepsia 51:883–890
2. Pitkänen A, Ekolle Ndode-Ekane X, Lapinlampi N, Puhakka N (2018)
Epilepsy biomarkers - toward etiology and pathology specificity.
Neurobiol Dis 123:42–58
3. van Vliet EA, Aronica E, Vezzani A, Ravizza T (2018) Review:
neuroinflammatory pathways as treatment targets and biomarker
candidates in epilepsy: emerging evidence from preclinical and
clinical studies. Neuropathol Appl Neurobiol 44:91–111
4. Bertoglio D, Verhaeghe J, Dedeurwaerdere S, Gröhn O (2017)
Neuroimaging in animal models of epilepsy. Neuroscience 358:277–
299
5. Reddy S, Younus I, Sridhar V, Reddy D (2019) Neuroimaging
biomarkers of experimental epileptogenesis and refractory epilepsy.
Int J Mol Sci 20:220
6. Guo Y, Gao F, Wang S, Ding Y, Zhang H, Wang J, Ding MP (2009)
In vivo mapping of temporospatial changes in glucose utilization in rat
brain during epileptogenesis: an 18F-fluorodeoxyglucose–small ani-
mal positron emission tomography study. Neuroscience 162:972–979
7. Mirrione MM, Tsirka SE (2011) Neuroimaging in animal seizure
models with (18)FDG-PET. Epilepsy Res Treat 2011:369295
8. Koepp MJ, Årstad E, Bankstahl JP et al (2017) Neuroinflammation
imaging markers for epileptogenesis. Epilepsia 58:11–19
9. Bertoglio D, Verhaeghe J, Santermans E et al (2017) Non-invasive
PET imaging of brain inflammation at disease onset predicts
spontaneous recurrent seizures and reflects comorbidities. Brain
Behav Immun 61:69–79
10. Brackhan M, Bascuñana P, Ross TL et al (2018) [ 18 F]GE180
positron emission tomographic imaging indicates a potential double-
hit insult in the intrahippocampal kainate mouse model of temporal
lobe epilepsy. Epilepsia 59:617–626
11. Mercier J, Provins L, Valade A (2017) Discovery and development of
SV2A PET tracers: potential for imaging synaptic density and clinical
applications. Drug Discov Today Technol 25:45–52
12. Morris AWJ (2016) Brain imaging: synaptic density directly visual-
ized in human brains. Nat Rev Neurol 12:494–494
13. Rabiner EIA (2017) Imaging synaptic density: a different look at
neurological diseases. J Nucl Med 59(3):380–381
14. Finnema SJ, Nabulsi NB, Eid T et al (2016) Imaging synaptic density
in the living human brain. Sci Transl Med 8:348ra96
15. Bartholome O, Van den Ackerveken P, Sánchez Gil J et al (2017)
Puzzling out synaptic vesicle 2 family members functions. Front Mol
Neurosci 10:148
16. Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfán BV et al
(2013) Synaptic vesicle protein 2A: basic facts and role in synaptic
function. Eur J Neurosci 38:3529–3539
17. Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H (2016)
Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy
and beyond. CNS Drugs 30:1055–1077
18. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson
MR, Scheller RH, Chavkin C, Bajjalieh SM (1999) Abnormal
neurotransmission in mice lacking synaptic vesicle protein 2A
(SV2A). Proc Natl Acad Sci U S A 96:15268–15273
19. Janz R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and
SV2B function as redundant Ca2+ regulators in neurotransmitter
release. Neuron 24:1003–1016
20. Serajee FJ, Huq AM (2015) Homozygous mutation in synaptic vesicle
glycoprotein 2A gene results in intractable epilepsy, involuntary
movements, microcephaly, and developmental and growth retardation.
Pediatr Neurol 52:642–646.e1
21. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM,
Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the
binding site for the antiepileptic drug levetiracetam. Proc Natl Acad
Sci U S A 101:9861–9866
22. Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F,
Mievis F, Mestdagh N, Buchanan T, Valade A, Mercier J, Wood M,
Gillard M, Seret A, Luxen A, Salmon E, Plenevaux A (2014)
Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle
protein 2A in the brain. J Nucl Med 55:1336–1341
23. Bretin F, Bahri MA, Bernard C, Warnock G, Aerts J, Mestdagh N,
Buchanan T, Otoul C, Koestler F, Mievis F, Giacomelli F, Degueldre
C, Hustinx R, Luxen A, Seret A, Plenevaux A, Salmon E (2015)
Biodistribution and radiation dosimetry for the novel SV2A radio-
tracer [18F]UCB-H: first-in-human study. Mol Imaging Biol 17:557–
564
24. Becker G, Warnier C, Serrano ME, Bahri MA, Mercier J, Lemaire C,
Salmon E, Luxen A, Plenevaux A (2017) Pharmacokinetic character-
ization of [18F]UCB-H PET radiopharmaceutical in the rat brain. Mol
Pharm 14:2719–2725
25. Bahri MA, Plenevaux A, Aerts J et al (2017) Measuring brain synaptic
vesicle protein 2A with positron emission tomography and [ 18
F]UCB-H. Alzheimer’s Dement Transl Res Clin Interv 3:481–486
26. Bastin C, Bahri MA, Meyer F et al (2019) In vivo imaging of synaptic
loss in Alzheimer’s disease with [18F]UCB-H positron emission
tomography. Eur J Nucl Med Mol Imaging:1–13
27. Nabulsi NB, Mercier J, Holden D, Carré S, Najafzadeh S, Vander-
geten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F,
Laruelle M, Carson RE, Hannestad J, Huang Y (2016) Synthesis and
preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the
synaptic vesicle glycoprotein 2A in the brain. J Nucl Med 57:777–784
28. Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D,
Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE (2018)
Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a
novel radioligand for positron emission tomography imaging of
synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow
Metab 38:2041–2052
29. Levesque M, Avoli M (2013) The kainic acid model of temporal lobe
epilepsy. Neurosci Biobehav Rev 37:2887–2899
30. Nirwan N, Vyas P, Vohora D (2018) Animal models of status
epilepticus and temporal lobe epilepsy: a narrative review. Rev
Neurosci 29:757–770
31. Hellier JL, Dudek FE (2005) Chemoconvulsant model of chronic
spontaneous seizures. Curr Protoc Neurosci Chapter 9:Unit 9.19
32. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE (1998) Recurrent
spontaneous motor seizures after repeated low-dose systemic treat-
ment with kainate: assessment of a rat model of temporal lobe
epilepsy. Epilepsy Res 31:73–84
33. Racine RJ (1972) Modification of seizure activity by electrical
stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol
32:281–294
34. Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J,
Otabashi M, Bahri MA, Mercier J, Plenevaux A, Luxen A (2016)
Enabling efficient positron emission tomography (PET) imaging of
synaptic vesicle glycoprotein 2A (SV2A) with a robust and one-step
radiosynthesis of a highly potent 18F-labeled ligand ([18F]UCB-H). J
Med Chem 59:8955–8966
35. Serrano ME, Bahri MA, Becker G et al (2018) Quantification of
[18F]UCB-H binding in the rat brain: from kinetic modelling to
standardised uptake value. Mol Imaging Biol 21(5):888–897
36. Serrano ME, Becker G, Bahri MA et al (2019) Evaluating the in vivo
specificity in rats with microPET of [18F]UCB-H for the SV2A
protein, compared with SV2B and SV2C. Molecules 24(9):1705
37. Van Nieuwenhuyse B, Raedt R, Sprengers M et al (2015) The
systemic kainic acid rat model of temporal lobe epilepsy: long-term
EEG monitoring. Brain Res 1627:1–11
Serrano M.E. et al.: Longitudinal in vivo SV2A evaluation in temporal lobe epilepsy
38. Duricki DA, Soleman S, Moon LDF (2016) Analysis of longitudinal
data from animals with missing values using SPSS. Nat Protoc
11:1112–1129
39. Gröhn O, Pitkänen A (2007) Magnetic resonance imaging in animal
models of epilepsy-noninvasive detection of structural alterations.
Epilepsia 48(Suppl 4):3–10
40. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA (2009)
Decreased expression of synaptic vesicle protein 2A, the binding site
for levetiracetam, during epileptogenesis and chronic epilepsy.
Epilepsia 50:422–433
41. Hanaya R, Hosoyama H, Sugata S, Tokudome M, Hirano H,
Tokimura H, Kurisu K, Serikawa T, Sasa M, Arita K (2012) Low
distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the
cerebral cortex and hippocampus of spontaneously epileptic rats
exhibiting both tonic convulsion and absence seizure. Neuroscience
221:12–20
42. Feng G, Xiao F, Lu Y, Huang Z, Yuan J, Xiao Z, Xi Z, Wang X
(2009) Down-regulation synaptic vesicle protein 2A in the anterior
temporal neocortex of patients with intractable epilepsy. J Mol
Neurosci 39:354–359
43. Crèvecœur J, Kaminski RM, Rogister B et al (2014) Expression
pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with
temporal lobe epilepsy and hippocampal sclerosis. Neuropathol Appl
Neurobiol 40:191–204
44. Crèvecœur J, Foerch P, Doupagne M et al (2013) Expression of SV2
isoforms during rodent brain development. BMC Neurosci 14:87
45. Cavarsan CF, Malheiros J, Hamani C et al (2018) Is mossy fiber
sprouting a potential therapeutic target for epilepsy? Front Neurol
1(1):3–10
46. Beamer EH, Jurado-Arjona J, Jimenez-Mateos EM et al (2018)
MicroRNA-22 controls aberrant neurogenesis and changes in neuronal
morphology after status epilepticus. Front Mol Neurosci 11:442
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Serrano M.E. et al.: Longitudinal in vivo SV2A evaluation in temporal lobe epilepsy
